13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00616733 (ClinicalTrials.gov) | March 2008 | 4/2/2008 | 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients | An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: CS-0777 tablets | Daiichi Sankyo Inc. | NULL | Completed | 18 Years | 65 Years | Both | 25 | Phase 1 | United States |